user

Treatment Intensification by Stepwise Addition of Prandial Insulin Aspart to Once-Daily Basal Insulin Detemir in Subjects with Type 2 Diabetes: The STEPwise™ Trial

被引：0
|
作者：
Meneghini, Luigi F.
Hermansen, Kjeld
Mersebach, Henriette
Svendsen, Anne Louise
Kumar, Sudhesh
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A199 / A199
页数：1
相关论文
共 50 条
  • [41] Improved treatment satisfaction with once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated type 2 diabetes (ONWARDS 2)
    Polonsky, W.
    Benamar, M.
    Carstensen, L.
    Davies, M.
    Donatsky, A. M.
    Franek, E.
    Kellerer, M.
    Goldenberg, R.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S400 - S400
  • [42] Individual stepwise intensification of insulin analogue therapy in type 2 diabetes mellitus
    Ametov, A. S.
    Chernikova, N. A.
    [J]. DIABETES MELLITUS, 2012, 15 (04): : 89 - 94
  • [43] Observational Study of Once-Daily Insulin Detemir in People with Type 2 Diabetes Aged 75 Years or Older
    Karnieli, Eddy
    Baeres, Florian M. M.
    Dzida, Grzegorz
    Ji, Qiuhe
    Ligthelm, Robert
    Ross, Stuart
    Svendsen, Anne Louise
    Yale, Jean-Francois
    [J]. DRUGS & AGING, 2013, 30 (03) : 167 - 175
  • [44] Once-daily dosing of insulin detemir is associated with lower risk of hypoglycaemia at similar levels of HbA1c compared to once-daily NPH insulin in subjects with type 1 diabetes mellitus
    Shaw, J. E.
    Larsen, J.
    Pedersen, C. B.
    Tang-Fui, S.
    [J]. DIABETOLOGIA, 2008, 51 : S391 - S391
  • [45] Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials
    Raccah, Denis
    Lin, Jay
    Wang, Edward
    Germe, Maeva
    Perfetti, Riccardo
    Bonadonna, Riccardo C.
    de Pablos-Velasco, Pedro
    Roussel, Ronan
    Rosenstock, Julio
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (01) : 40 - 44
  • [46] Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes
    Vora, J.
    Caputo, S.
    Damci, T.
    Orozco-Beltran, D.
    Pan, C.
    Svendsen, A. L.
    Solje, K. S.
    Khunti, K.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (02) : 136 - 143
  • [47] Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus
    Jeong, In-Kyung
    Chung, Choon Hee
    Zhou, Zhiguang
    Han, Jeong Hee
    Duan, Ran
    Edralin, Diana M.
    Rodriguez, Angel
    [J]. JOURNAL OF DIABETES, 2017, 9 (04) : 396 - 404
  • [48] Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
    Philis-Tsimikas, Athena
    Charpentier, Guillaume
    Clauson, Per
    Ravn, Gabriela Martinez
    Roberts, Victor Lawrence
    Thorsteinsson, Birger
    [J]. CLINICAL THERAPEUTICS, 2006, 28 (10) : 1569 - 1581
  • [49] Less weight gain and hypoglycaemia with once-daily insulin detemir than with NPH insulin in basal-bolus therapy of overweight type 2 diabetes patients: The PREDICTIVE-BMT trial
    Montanana, C. Fajardo
    Herrero, C. Hernandez
    Fernandez, M. Rivas
    [J]. DIABETOLOGIA, 2007, 50 : S404 - S404
  • [50] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once daily in basal-bolus treatment with insulin aspart in type 1 diabetes
    Hirsch, I.
    Franek, E.
    Courreges, J. P.
    Mersebach, H.
    Dykiel, P.
    Bode, B. W.
    [J]. DIABETOLOGIA, 2011, 54 : S427 - S427
12345